next gen glp 1 Pharma Giants Bet on Next-Generation GLP-1 Treatments to Sustain Growth GLP-1-based therapies for diabetes, obesity

Gastrointestinal adverse effects are the most frequently reported and include: Nausea (very common, affecting more than 1 in 10 people according to the SmPC) Vomiting Diarrhoea Constipation Abdominal pain or discomfort These symptoms are usually mild to moderate, transient, and tend to improve over time as the body adjusts to the medication

M., Chung, J

Insurers have obviously used claims denials as a tool to manage costs and control their MLRs for years, ratcheting up focus on this particular profit lever in difficult financial times

[2,109] A study has shown that only 25% of gut produced endogenous GLP-1 reaches the portal circulation intact, whereas further cleavage happens in the liver causes an additional 40%50% reduction of intact GLP-1, leading to only 10%15% of those enters the systemic circulation

Clinicians also prescribe the drugs for weight loss in people without type 2 diabetes